Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review
Hannah W. Haddad, Garett W. Malone, Nicholas J. Comardelle, et al.
Health psychology research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Davis Cammann, et al.
BioDrugs (2023) Vol. 38, Iss. 1, pp. 5-22
Open Access | Times Cited: 127
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
Karolina Wojtunik‐Kulesza, Monika Rudkowska, Anna Orzeł-Sajdłowska
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4367-4367
Open Access | Times Cited: 44
Understanding neuropsychiatric symptoms in Alzheimer’s disease: challenges and advances in diagnosis and treatment
Andrew Pless, Destany Ware, Shalini Saggu, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 43
Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications
Paras Mani Giri, Anurag Banerjee, Arpita Ghosal, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3995-3995
Open Access | Times Cited: 30
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 21
Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
Ashvin Varadharajan, Aarjith Damian Davis, Aishwarya Ghosh, et al.
Journal of Neurosciences in Rural Practice (2023) Vol. 14, pp. 566-573
Open Access | Times Cited: 32
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Faizan Ahmad, Anik Karan, Rashi Sharma, et al.
Ageing Research Reviews (2024) Vol. 95, pp. 102229-102229
Closed Access | Times Cited: 15
Pathogenesis, Diagnostics, and Therapeutics for Alzheimer's Disease: Breaking the Memory Barrier
Pushpa Tryphena Kamatham, Rashi K. Shukla, Dharmendra Kumar Khatri, et al.
Ageing Research Reviews (2024) Vol. 101, pp. 102481-102481
Open Access | Times Cited: 14
Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease
Antea Kršek, Lara Batičić
Future Pharmacology (2024) Vol. 4, Iss. 2, pp. 352-379
Open Access | Times Cited: 10
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Taha Basit Ameen, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, et al.
The Egyptian Journal of Neurology Psychiatry and Neurosurgery (2024) Vol. 60, Iss. 1
Open Access | Times Cited: 9
Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model
Samantha Rossano, Aubrey S. Johnson, Anna Smith, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 4, pp. 2397-2407
Open Access | Times Cited: 8
Nrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease
Priyanka Soni, Sudarshana M. Sharma, Andrew A. Pieper, et al.
Neurotherapeutics (2025), pp. e00586-e00586
Open Access | Times Cited: 1
Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review
Jakub Hort, Thomas Duning, Robert Hoerr
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 647-660
Open Access | Times Cited: 19
The complement system in neurodegenerative diseases
Jacqui Nimmo, Robert A. J. Byrne, Nikoleta Daskoulidou, et al.
Clinical Science (2024) Vol. 138, Iss. 6, pp. 387-412
Open Access | Times Cited: 7
Therapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
Anna Atlante, Giuseppina Amadoro, Valentina Latina, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 22, pp. 6742-6742
Open Access | Times Cited: 23
Transcranial alternating current stimulation combined with sound stimulation improves cognitive function in patients with Alzheimer’s disease: Study protocol for a randomized controlled trial
Yang Liu, Shuzhen Liu, Can Tang, et al.
Frontiers in Aging Neuroscience (2023) Vol. 14
Open Access | Times Cited: 15
Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions
Nour S. Tobeh, Kimberley D. Bruce
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 14
Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers
Mohammad Azam Ansari, Takshashila Tripathi, Baskar Venkidasamy, et al.
Molecular Neurobiology (2023) Vol. 61, Iss. 5, pp. 3042-3089
Closed Access | Times Cited: 14
Monoclonal Antibody Therapy in Alzheimer’s Disease
Monica Neațu, Anca Covaliu, Iulia Ioniță, et al.
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 60-60
Open Access | Times Cited: 14
Curcumin-derived carbon quantum dots: Dual actions in mitigating tau hyperphosphorylation and amyloid beta aggregation
Jie Lay Lim, Chin‐Jung Lin, Chih‐Ching Huang, et al.
Colloids and Surfaces B Biointerfaces (2023) Vol. 234, pp. 113676-113676
Closed Access | Times Cited: 13
Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease
Eva Mezeiová, Lukáš Prchal, Martina Hrabinová, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116399-116399
Open Access | Times Cited: 5
Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab
Elysia Chin, Ecler Jaqua, Mary Safaeipour, et al.
Cureus (2022)
Open Access | Times Cited: 21
Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
Wioleta M. Zelek, Ryan J. Bevan, B. Paul Morgan
Brain Behavior and Immunity (2024) Vol. 118, pp. 355-363
Open Access | Times Cited: 4
Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model
Wioleta M. Zelek, Ryan J. Bevan, Jacqui Nimmo, et al.
Brain (2024)
Open Access | Times Cited: 4
Promising Natural Remedies for Alzheimer’s Disease Therapy
Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, et al.
Molecules (2025) Vol. 30, Iss. 4, pp. 922-922
Open Access
Page 1 - Next Page

Scroll to top